Highlights GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Real-time Estimate Cboe BZX Other stock markets 02:24:26 2024-04-29 pm EDT			5-day change	1st Jan Change
1.595 ^USD	-2.74%		-10.56%	-31.78%

Mar. 27	Transcript : GlycoMimetics, Inc., Q4 2023 Earnings Call, Mar 27, 2024
Mar. 27	GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
GlycoMimetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
GlycoMimetics, Inc. Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1A Healthy Volunteer Study of GMI-1687	Jan. 04	CI
GlycoMimetics, Thermo Fisher Unit Set Accord for Manufacturing Uproleselan for Acute Myeloid Leukemia	Jan. 02	MT
GlycoMimetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687	23-09-06	CI
GlycoMimetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia	23-06-15	CI
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03	CI
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee	23-02-15	CI
GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting	22-12-12	CI
GlycoMimetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Earnings Flash (GLYC) GLYCOMIMETICS Posts Q2 Loss $-0.25	22-08-03	MT
GlycoMimetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-03	CI
Earnings Flash (GLYC) GLYCOMIMETICS Posts Q1 Loss $-0.28, vs. Street Est of $-0.32	22-04-28	MT
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-03	CI
Earnings Flash (GLYC) GLYCOMIMETICS Reports Q4 Loss $-0.33, vs. Street Est of $-0.34	22-03-03	MT
GlycoMimetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-03-03	CI
GlycoMimetics, Inc. Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia	21-11-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Highlights

Filters